- 期刊
Osimertinib Combined with Cetuximab for T790M and C797S Mutation in Non-small Cell Lung Cancer-Case Series
摘要
Osimertinib, a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is proven to be effective in managing T790M mutation in non-small cell lung cancer (NSCLC). However, osimertinib becomes resistant when both T790M and C797S mutations are present. Our goal was to evaluate the treatment response of T790M and C797S-positive NSCLC treated with osimertinib and cetuximab. A retrospective chart review of EGFR T790M and C797S mutations positive NSCLC patients, treated with osimertinib and cetuximab at National Taiwan University Hospital, from July 2017 to October 2018 was performed. Four patients with NSCLC carried EGFR T790M and C797S mutations. They were all treated with osimertinib and cetuximab. Progression-free survival of these patients was 6.7, 4.9, 4.1 and 1 month, respectively. Osimertinib, combined with cetuximab seems to be beneficial for NSCLC patients with acquired T790M and C797S positive NSCLC. Further studies are necessary in order to understand the mechanism.
延伸閱讀
- Urgard, E., Vooder, T., Võsa, U., Välk, K., Liu, M., Luo, C., Hoti, F., Roosipuu, R., Annilo, T., Laine, J., Frenz, C. M., Zhang, L., & Metspalu, A. (2011). Metagenes Associated with Survival in Non-Small Cell Lung Cancer. Cancer Informatics, (2011), 175-183. https://doi.org/10.4137/CIN.S7135
- Chung, C. Y., Hsu, N. C., Horng, H. C., Chen, M. L., & Chang, C. S. (2005). Successful Pregnancy Following Chemotherapy with Gemcitabine for Advanced Non-Small Cell Lung Cancer. The Changhua Journal of Medicine, 10(1), 39-41. https://www.airitilibrary.com/Article/Detail?DocID=16801504-200501-10-1-39-41-a
- Gomez, D. R., Niibe, Y., & Chang, J. Y. (2012). Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer. Pulmonary Medicine, 2012(), 244-249. https://doi.org/10.1155/2012/396592
- Tadokoro, A., Kanaji, N., Ishii, T., Watanabe, N., Inoue, T., Kadowaki, N., & Bandoh, S. (2015). Transbronchial Dissemination of Squamous Cell Lung Cancer. Clinical Medicine Insights: Oncology, (), 129-133. https://doi.org/10.4137/CMO.S32707
- 楊麗柔、蔡芳佩、彭姿蓉（2020）。Treatment of ALK Positive in Advanced-stage Non-small Cell Lung Cancer。內科學誌，31(6)，398-404。https://doi.org/10.6314/JIMT.202012_31(6).03